The company in question is, Incyte Corporation (NASDAQ:INCY) currently with a stock price of 86.7 (-0.46% today). The market cap for Incyte Corporation is 16754.77, and is in the sector Healthcare, and Biotechnology industry. The target price for Incyte Corporation is 104.27. Currently Incyte Corporation is trading with a P/E of 255.75, and a forward P/E of 62.2. Average volume for Incyte Corporation is 1308.97 and so far today it is 1229800.
Performance in the last year for Incyte Corporation has been -19.56%. For EPS growth, Incyte Corporation has seen a growth of 112.10%, and is looking to grow in the next year to 597.00%. More long term stats show that EPS growth has been 16.40% over the last five years and could be 58.26% for the next five years. Incyte Corporation has seen sales growth quarter over quarter at 51.10%, with EPS growth quarter over quarter at 257.80%. The 20-day simple moving average is 1.63%, with the 200-day simple moving average coming to 8.73%.
Since the IPO date for Incyte Corporation on the 11/4/1993, Incyte Corporation has seen performance year to date to be -20.06%. With Incyte Corporation trading at 86.7, the dividend yield is *TBA, and the EPS is 0.34.
So could Incyte Corporation, be undervalued? Well as said before P/E is 255.75. The PEG is 4.39, P/S is 17.8 and the P/B is at 54.87. The P/cash is 26.63, with P/free cash flow at 197.58.
Incyte Corporation ability to deal with debt shows that the current ratio is 4, and the quick ratio is 4. This is with long term debt/equity at 2.14, and total debt/equity at 0.
In terms of margins, Incyte Corporation has a gross margin of 96.20%, an operating margin of 15.50% and a profit margin of 7.90%.Payout ratio for Incyte Corporation is 0.00%. Return on assets come to 6.60% with return on investment coming to 6.30%.
Insider ownership for Incyte Corporation, is at 0.50% and institutional ownership comes to 97.10%. Outstanding shares are at 193.25. While shares float is 186.67. The float short is currently 2.83%, and short ratio is 4.03.